Erratum: PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum

Int J Med Sci. 2022 Mar 3;19(3):486-487. doi: 10.7150/ijms.71614. eCollection 2022.

Authors

Peng Du¹, Kaifeng Luo¹, Guoyong Li¹, Jisheng Zhu¹, Qi Xiao¹, Yong Li¹, Xingjian Zhang¹

Affiliation

¹ Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.

Abstract

[This corrects the article DOI: 10.7150/ijms.62467.].

© The author(s).

Publication types

Published Erratum